Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

A recent trial reveals that Ozempic, a GLP-1 diabetes medication, may help reduce alcohol cravings and consumption in individuals with alcohol use disorder, highlighting its potential beyond diabetes ...

Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more and more cases linking them ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper ...